Advances in therapeutic drugs for nonalcoholic steatohepatitis
DOI:10.3969/j.issn.1001-5256.2020.12.039
- VernacularTitle:非酒精性脂肪性肝炎治疗药物的进展
- Author:
Shuaijie QIAN
1
;
Jinyue GU
;
Jinhang GAO
;
Huan TONG
Author Information
1. West China Medical School, Sichuan University, Chengdu 610041, China
- Publication Type:Research Article
- Keywords:
non-alcoholic steatohepatitis;
drug therapy;
randomized controlled trials as topic
- From:
Journal of Clinical Hepatology
2020;36(12):2826-2830
- CountryChina
- Language:Chinese
-
Abstract:
The incidence rate of nonalcoholic steatohepatitis is gradually increasing year by year, which calls for an urgent need for effective therapeutic drugs. In recent years, various drugs have been developed, including anti-oxidative stress drugs, insulin sensitizers, PPAR agonists, thyroid receptor agonists, farnesoid X receptor agonists, ASK1 inhibitors, and pan-caspase inhibitors. This article reviews the clinical studies on the therapeutic drugs for nonalcoholic steatohepatitis and summarizes the efficacy and safety of each drug, in order to provide a reference for clinical practice.
